Amgen says drug slowed ovarian cancer in trial

(Reuters) - Amgen Inc's trebananib drug for ovarian cancer extended the length of time that patients lived without the disease getting worse by about two months, meeting the main goal of a late-stage clinical trial, the company said on Wednesday.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/BHS7FxL1w4A/story01.htm

phlebotomy tech schools phlebotomy training in arizona phlebotomy licensing